PRPH - ProPhase Labs, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

PRPH

PROPHASE LABS, INC.

OTC

$0.02

▼ DOWN 33.33% (-0.01)

KEY STATISTICS

Market Cap$280.32 K

52w High$6.70

52w Low$0.02

Dividend Yield14.35%

FrequencySpecial

P/E-0.01

Volume74.11K

Shares Out.14.02M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Ted William Karkus

COMPENSATION 2026

Salary$675,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$28,200

Total$2,123,200

ABOUT

SECTOR

Healthcare

WENT PUBLIC

April 4, 1994

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$140.00

Target Low$140.00

Target Median$140.00

Target Consensus$140.00

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.—

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2025-12-22	Reverse	1:10
1997-01-23	Forward	2:1
1996-01-11	Reverse	1:10

PRICE

$0.02 ▼ DOWN 33.33% (−$0.01)

OVERLAYS

About ProPhase Labs, Inc.

https://www.prophaselabs.com ↗

ProPhase Labs, Inc. develops, manufactures, and markets OTC healthcare products, dietary supplements, and diagnostic testing services, including COVID-19 tests, serving retail and healthcare markets in the U.S.

INDUSTRY

Medical - Pharmaceuticals

A PRODUCT PROPHASE LABS, INC. IS KNOWN FOR

BE-Smart™

BE-Smart™ is a clinically validated LDT for early esophageal cancer detection, helping assess risk, with ProPhase Labs seeking a sale or strategic partnership to advance its commercialization.